海藻酸钠微球血管栓塞剂治疗原发性肝癌36例分析.docVIP

意见：结果太简单，就一个表，要3个表，讨论围绕结果写。参考文献引用实用癌症杂志一篇。 海藻酸钠微球栓塞治疗中晚期原发性肝癌36例分析 目的: 评价海藻酸钠微球(kelp micro gelation, KMG)栓塞治疗中晚期原发性肝癌的疗效及不良反应。方法: 采用肝动脉化疗栓塞术（transcatheter hepatic artery chemoembolization,TACE)治疗36例原发性肝癌患者，应用蒽环类药物、铂类药物及羟基喜树碱化疗，海藻酸钠微球进行栓塞，评价近期疗效，统计1年生存率，分析不良反应。结果: 36例患者经海藻酸钠微球栓塞治疗后肿瘤完全缓解（CR)8.33%（3/36），部分缓解(PR)47.22%（17/36），疾病稳定（SD）36.11%（13/36），疾病进展（PD）8.33%（3/36），1年生存率77.78%。常见的不良反应是肝区疼痛55.56%（20/36），发热47.22%（17/36），恶心呕吐58.33%（21/36），肝功能异常41.67%（15/36)，但多为轻中度，无异位栓塞等严重并发症和治疗相关死亡。结论: 海藻酸钠微球栓塞治疗中晚期原发性肝癌安全、有效, 延长患者生存，可作为中晚期原发性肝癌栓塞治疗的新选择。 关键词: 海藻酸钠微球；原发性肝癌；肝动脉栓塞； Objective: To evaluation the efficacy and adverse reactions of kelp micro gelation (KMG) in treating advanced primary liver cancer. Methods: 36 cases of primary liver cancer patients were treated with transcatheter hepatic artery chemoembolization, which applied anthracyclines, platinum-based chemotherapy drugs and HCPT, along with kelp micro gelation for embolization. Then, the short term effect was evaluated; one-year survival rate and adverse reactions were analyzed. Result: Among of 36 patients, complete response (CR) accounted for 8.33% (3/36), partial remission (PR) accounted for 47.22% (17/36), stable disease (SD) accounted for 36.11% (13/36), disease progression (PD) accounted for 8.33% (3/36), and 1-year survival rate was 77.78%. Common adverse reactions were liver pain 55.56% (20/36), fever 47.22% (17/36), nausea and vomiting 58.33% (21/36), abnormal liver function 41.67% (15/36). Most adverse reactions were mild or moderate, and no serious treatment-related complications and death occurred. Conclusion: Kelp micro gelation embolism is safe and effective and may prolong survival in advanced primary liver cancer patients, which could be as a new choice for advanced primary liver cancer embolization. Keywords: kelp micro gelation ;primary liver ; hepatic artery embolization 原发性肝癌（primary hepatic carcinoma,PHC）是一种常见的恶性肿瘤，大多数患者就诊时已属中晚期,手术切除率很低,术后复发率高。肝动脉化疗栓塞术（transcatheter hepatic artery chemoembolizat